C5a receptor inhibitor avacopan in immunoglobulin A nephropathy—an open-label pilot study

BACKGROUND: Improvement of proteinuria as a marker for disease activity is associated with a better renal outcome in immunoglobulin A nephropathy (IgAN). Complement is an effector pathway in IgA-mediated kidney injury. Avacopan, a selective C5a receptor inhibitor, has previously shown efficacy in an...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruchfeld, Annette, Magin, Hasan, Nachman, Patrick, Parikh, Samir, Lafayette, Richard, Potarca, Antonia, Miao, Shichang, Bekker, Pirow
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050557/
https://www.ncbi.nlm.nih.gov/pubmed/35498891
http://dx.doi.org/10.1093/ckj/sfab294

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050557/
https://www.ncbi.nlm.nih.gov/pubmed/35498891
http://dx.doi.org/10.1093/ckj/sfab294

Ejemplares similares